Edrecolomab

Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research[1][2].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC)[1]. Cell Cytotoxicity Assay[1] Cell Line: KATO III cells Concentration: 0-100 μg/mL Incubation Time: 20 hours Result: Exhibited an ED50 value>100 ng/ml.

Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model[1]. Animal Model: Male nu/nu mice injected with HT-29 colon carcinoma cells[1] Dosage: 30 μg/dose Administration: Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation Result: Inhibited tumor growth with a number of significant readings (p≤0.05).

[1]. Naundorf S, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002 Jul 1;100(1):101-10.

[2]. Punt CJ, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002 Aug 31;360(9334):671-7.